COVID-19 therapy: What works? What doesn’t? And what’s on the horizon?

,; ,; ,

doi:doi: 10.12788/jfp.0474

Applied Evidence

COVID-19 therapy: What works? What doesn’t? And what’s on the horizon?

J Fam Pract. 2022 September;71(7):E3-E16 | doi: 10.12788/jfp.0474

PDF Download

References

1. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. July 19, 2022. Accessed July 21, 2022. www.covid19treatmentguidelines.nih.gov

2. IDSA guidelines on the treatment and management of patients with COVID-19. Infectious Diseases Society of America. Updated June 29, 2022. Accessed July 21, 2022. www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-23

3. Therapeutics and COVID-19: living guideline. World Health Organization. July 14, 2022. Accessed July 21, 2022. https://apps.who.int/iris/rest/bitstreams/1449398/retrieve

4. Centers for Disease Control and Prevention. Clinical care considerations. Updated May 27, 2022. Accessed July 21, 2022. www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

5. Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. Press release. US Food and Drug Administration. April 25, 2022. Accessed August 11, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children

6. Know your treatment options for COVID-19. US Food and Drug Administration. Updated August 15, 2022. Accessed July 21, 2022. www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19

7. Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA. 2022;327:384-385. doi: 10.1001/jama.2021.24931

8. Judson TJ, Odisho AY, Neinstein AB, et al. Rapid design and implementation of an integrated patient self-triage and self-scheduling tool for COVID-19. J Am Med Inform Assoc. 2020;27:860-866. doi: 10.1093/jamia/ocaa051

9. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383:1757-1766. doi: 10.1056/NEJMcp2009249

10. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ. 2020;368:m1182. doi: 10.1136/bmj.m1182

11. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al; MOVe-OUT Study Group. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-520. doi: 10.1056/NEJMoa2116044

12. Hammond J, Leister-Tebbe H, Gardner A, et al; EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-1408. doi: 10.1056/NEJMoa2118542

13. Gottlieb RL, Vaca CE, Paredes R, et al; GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305-315. doi: 10.1056/NEJMoa2116846

14. Gupta A, Gonzalez-Rojas Y, Juarez E, et al; COMET-ICE Investigators. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941-1950. doi: 10.1056/NEJMoa2107934

15. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173:623-631. doi: 10.7326/M20-4207

16. Scheen AJ. Statins and clinical outcomes with COVID-19: meta-analyses of observational studies. Diabetes Metab. 2021;47:101220. doi: 10.1016/j.diabet.2020.101220

17. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020;134:153-155. doi: 10.1016/j.amjcard.2020.08.004

18. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55:2001009. doi: 10.1183/13993003.01009-2020

19. Yu L-M, Bafadhel M, Dorward J, et al; PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398:843-855. doi: 10.1016/S0140-6736(21)01744-X

20. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021;374:n2231. doi: 10.1136/bmj.n2231

21. Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi: 10.1136/bmj.m2980

22. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379

23. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021;34:155-170. doi: 10.1089/jamp.2020.1659

24. Schultze A, Walker AJ, MacKenna B, et al; OpenSAFELY Collaborative. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8:1106-1120. doi: 10.1016/S2213-2600(20)30415-X

25. What are the safety and efficacy results of bebtelovimab from BLAZE-4? Lilly USA. January 12, 2022. Accessed August 17, 2022. www.lillymedical.com/en-us/answers/what-are-the-safety-and-efficacy-results-of-bebtelovimab-from-blaze-4-159290

26. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813-1826. doi: 10.1056/NEJMoa2007764

27. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787-1799. doi: 10.1056/NEJMoa2001282

28. Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA. 2022;327:617-618. doi: 10.1001/jama.2022.0335

29. Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516-523. doi: 10.1080/07853890.2022.2034936

30. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022:602:671-675. doi: 10.1038/s41586-021-04389-z

31. Emergency use authorization (EUA) for bebtelovimab (LY-CoV1404): Center for Drug Evaluation and Research (CDER) review. US Food and Drug Administration. Updated February 11, 2022. Accessed July 21, 2022. www.fda.gov/media/156396/download

32. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:n949. doi: 10.1136/bmj.n949

33. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al; TOGETHER Investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42-e51. doi: 10.1016/S2214-109X(21)00448-4

34. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049-2059. doi: 10.1016/S0140-6736(21)00897-7

35. Simonovich VA, Burgos Pratx LD, Scibona P, et al; PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619-629. doi: 10.1056/NEJMoa2031304

36. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015-1027. doi: 10.1056/NEJMoa2031893

37. Ayeh SK, Abbey EJ, Khalifa BAA, et al. Statins use and COVID-19 outcomes in hospitalized patients. PLoS One. 2021;16:e0256899. doi: 10.1371/journal.pone.0256899

38. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9:763-772. doi: 10.1016/S2213-2600(21)00160-0

39. Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of Covid-19. N Engl J Med. 2021;385:2197-2198. doi: 10.1056/NEJMc2114907

40. Thomas S, Patel D, Bittel B, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw Open. 2021;4:e210369. doi: 10.1001/jamanetworkopen.2021.0369

41. Adams KK, Baker WL, Sobieraj DM. Myth busters: dietary supplements and COVID-19. Ann Pharmacother. 2020;54:820-826. doi: 10.1177/1060028020928052

42. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo A-M, et al. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384:497-511. doi: 10.1056/NEJMoa2023184

43. Kalil AC, Patterson TF, Mehta AK, et al; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795-807. doi: 10.1056/NEJMoa2031994

44. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330-1341. doi: 10.1001/jama.2020.17023

45. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499-518. doi: 10.1001/jama.2021.11330

46. Wei QW, Lin H, Wei R-G, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10:71. doi: 10.1186/s40249-021-00857-w

47. Zhang X, Shang L, Fan G, et al. The efficacy and safety of Janus kinase inhibitors for patients with COVID-19: a living systematic review and meta-analysis. Front Med (Lausanne). 2021;8:800492. doi: 10.3389/fmed.2021.800492

48. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645. doi: 10.1016/S0140-6736(21)00676-0

49. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491-1502. doi: 10.1056/NEJMoa2100433

50. Guimaraes PO, Quirk D, Furtado RH, et al; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385:406-415. doi: 10.1056/NEJMoa2101643

51. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334-346. doi: 10.1056/NEJMoa2021680

52. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320

53. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175:817-826. doi: 10.1001/jamapediatrics.2021.1050

54. Jorgensen SCJ, Davis MR, Lapinsky SE. A review of remdesivir for COVID-19 in pregnancy and lactation. J Antimicrob Chemother. 2021;77:24-30. doi: 10.1093/jac/dkab311

55. Management considerations for pregnant patients with COVID-19. Society for Maternal-Fetal Medicine. Accessed July 21, 2022. https://s3.amazonaws.com/cdn.smfm.org/media/2336/SMFM_COVID_Management_of_COVID_pos_preg_patients_4-30-20_final.pdf

Tocilizumab. A monoclonal antibody and interleukin (IL)-6 inhibitor, tocilizumab is also recommended in addition to dexamethasone, with or without remdesivir.⁴⁸ Tocilizumab should be given only in combination with dexamethasone.⁴⁹ Patients should receive baricitinib or tocilizumab—not both. IDSA recommends tofacitinib, with a prophylactic dose of an anticoagulant, for patients who are hospitalized with severe COVID-19 but who are not on any form of ventilation.⁵⁰

Care of special populations

Special patient populations often seek primary care. Although many questions remain regarding the appropriate care of these populations, it is useful to summarize existing evidence and recommendations from current guidelines.

Children. COVID-19 is generally milder in children than in adults; many infected children are asymptomatic. However, infants and children who have an underlying medical condition are at risk of severe disease, including multisystem inflammatory syndrome.⁵¹

Because patients with COVID-19 experience a range of illness severity, they should be monitored for progression, remotely or in person, until fully recovered.

The NIH panel recommends supportive care alone for most children with mild-to-moderate disease.¹ Remdesivir is recommended for hospitalized children ≥ 12 years who weigh ≥ 40 kg, have risk factors for severe disease, and have an emergent or increasing need for supplemental oxygen. Dexamethasone is recommended for hospitalized children requiring high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation. Molnupiravir is not authorized for patients < 18 years because it can impede bone and cartilage growth.

There is insufficient evidence for or against the use of monoclonal antibody products for children with COVID-19 in an ambulatory setting. For hospitalized children, there is insufficient evidence for or against use of baricitinib and tocilizumab.

Continue to: Patients who are pregnant